Humira off label uses?

When does Humira's patent expire?
Key patents for Humira (adalimumab) have already expired or are set to expire soon, paving the way for biosimilar competition. For instance, the primary composition of matter patent expired in 2016, and other related patents are expiring through 2023 [1].

What are the approved uses for Humira?
Humira is approved to treat several autoimmune conditions. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa [2]. It is also used for uveitis and juvenile idiopathic arthritis [2].

What are the challenges to Humira's patents?
Companies have challenged Humira's patents through various legal mechanisms, including inter partes reviews (IPRs). These challenges aim to invalidate or narrow the scope of existing patents, which can accelerate the entry of biosimilar versions [1].

What are the off-label uses being investigated for Humira?
While not officially approved by regulatory bodies, some physicians may prescribe Humira for conditions other than its approved indications, a practice known as off-label use. Research has explored its potential in treating other inflammatory and autoimmune diseases, though specific off-label uses are not widely documented in public scientific literature without proprietary research context.

Can biosimilars enter the market before patent expiry?
The entry of biosimilars is directly tied to patent expiry and legal challenges. When patents expire or are invalidated, biosimilar manufacturers can seek approval from regulatory agencies like the FDA. The timeline for biosimilar market entry can be complex due to patent litigation [1].

Where can I find more information on drug patents?
DrugPatentWatch.com provides comprehensive data on drug patents, including expiration dates and patent litigation, offering insights into the intellectual property landscape for medications like Humira [1].

Sources:
[1] DrugPatentWatch.com
[2] AbbVie Inc.